Luca Faloppi

List of Publications by Year
in descending order

94 papers	2,046 citations	201575 27 h-index	265120 42 g-index
97 all docs	97 docs citations	97 times ranked	3590 citing authors

#	Article	IF	Citations
1	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	2.3	109
2	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. British Journal of Cancer, 2012, 106, 799-804.	2.9	97
3	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget, 2016, 7, 67142-67149.	0.8	91
4	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer, 2014, 14, 110.	1.1	80
5	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	1.3	76
6	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596.	2.0	76
7	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British Journal of Cancer, 2013, 108, 1126-1132.	2.9	71
8	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	0.9	66
9	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
10	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer, 2017, 20, 156-163.	2.7	62
11	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opinion on Therapeutic Targets, 2015, 19, 1623-1635.	1.5	58
12	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules, 2014, 19, 6393-6406.	1.7	56
13	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. Cancer Treatment Reviews, 2011, 37, 169-177.	3.4	49
14	The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. PLoS ONE, 2012, 7, e32653.	1.1	47
15	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	0.8	46
16	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. BioMed Research International, 2016, 2016, 1-7.	0.9	45
17	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.4	40
18	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	0.8	40

#	Article	IF	Citations
19	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of Experimental and Clinical Cancer Research, 2010, 29, 164.	3.5	39
20	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. European Journal of Cancer, 2019, 111, 94-106.	1.3	36
21	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE, 2013, 8, e72843.	1.1	36
22	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	1.1	33
23	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	1.6	30
24	eNOSpolymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget, 2016, 7, 27988-27999.	0.8	30
25	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	1.1	29
26	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer, 2016, 16, 429.	1.1	28
27	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology, 2013, 88, 272-283.	2.0	27
28	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget, 2016, 7, 15243-15251.	0.8	26
29	Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2012, 10, 71.	1.8	25
30	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	1.6	25
31	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treatment Reviews, 2009, 35, 451-462.	3.4	24
32	Role of SIRT-3, p-mTOR and HIF-1Î± in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. International Journal of Molecular Sciences, 2019, 20, 1503.	1.8	24
33	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	1.7	23
34	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology, 2018, 129, 44-53.	2.0	23
35	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 2019, 11, 1023.	1.7	23
36	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports, 2016, 6, 24136.	1.6	22

#	Article	IF	Citations
37	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.3	22
38	Prognostic Value for Incidental Antihypertensive Therapy With Î²-Blockers in Metastatic Colorectal Cancer. Medicine (United States), 2015, 94, e719.	0.4	18
39	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 2017, 16, 38-43.	1.0	18
40	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics, 2013, 14, 1991-1998.	0.6	17
41	Cetuximab: still an option in the treatment of pancreatic cancer?. Expert Opinion on Biological Therapy, 2013, 13, 791-801.	1.4	17
42	The â€œangiogenetic ladderâ€, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews, 2014, 40, 934-941.	3.4	16
43	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. PLoS ONE, 2012, 7, e38192.	1.1	15
44	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	1.7	15
45	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. PLoS ONE, 2013, 8, e78544.	1.1	14
46	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	1.7	14
47	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, 104, 476-479.	0.6	14
48	Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget, 2016, 7, 37599-37607.	0.8	14
49	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. Current Oncology Reports, 2010, 12, 175-185.	1.8	13
50	Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2017, 62, 1872-1880.	1.1	13
51	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	3.2	13
52	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€”Final results of the ALICE-2 study.. Journal of Clinical Oncology, 2016, 34, 280-280.	0.8	13
53	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. British Journal of Cancer, 2022, 126, 1783-1794.	2.9	12
54	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	0.9	11

#	Article	IF	Citations
55	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. SpringerPlus, 2015, 4, 743.	1.2	10
56	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. Critical Reviews in Oncology/Hematology, 2013, 85, 332-341.	2.0	8
57	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opinion on Pharmacotherapy, 2014, 15, 143-150.	0.9	7
58	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Therapeutic Advances in Urology, 2019, 11, 175628721881537.	0.9	7
59	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. Current Drug Targets, 2014, 15, 1225-1230.	1.0	7
60	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2015, 13, 140.	1.8	6
61	Panitumumab for the treatment of metastatic colorectal cancer: a review. Immunotherapy, 2015, 7, 721-738.	1.0	6
62	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	0.6	6
63	Role of Î²4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. Future Oncology, 2013, 9, 1207-1214.	1.1	5
64	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	1.0	5
65	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Tumori, 2021, 107, 550-555.	0.6	5
66	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.4	4
67	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Gastrointestinal Tumors, 2019, 6, 71-80.	0.3	4
68	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Digestive and Liver Disease, 2012, 44, 74-79.	0.4	3
69	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	0.6	3
70	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2017, 35, e15666-e15666.	0.8	3
71	Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78.	0.4	2
72	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta OncolÃ³gica, 2021, 60, 1317-1324.	0.8	2

#	Article	IF	Citations
73	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2014, 32, 497-497.	0.8	2
74	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 595-595.	0.8	1
75	Expression of stem cell markers in pancreatic ductal adenocarcinoma and clinical relevance.. Journal of Clinical Oncology, 2013, 31, e15058-e15058.	0.8	1
76	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of Chemotherapy, 2022, 34, 543-549.	0.7	1
77	Palliative Treatment. , 2012, , 209-214.		0
78	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. Journal of Clinical Oncology, 2012, 30, 449-449.	0.8	0
79	Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 474-474.	0.8	0
80	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 64-64.	0.8	0
81	Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study.. Journal of Clinical Oncology, 2015, 33, 596-596.	0.8	0
82	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.. Journal of Clinical Oncology, 2015, 33, 313-313.	0.8	0
83	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2015, 33, 591-591.	0.8	0
84	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, 230-230.	0.8	0
85	Angiogenic profile and pathological features in the prediction of clinical outcome of advanced renal cell carcinoma patients receiving sunitinib.. Journal of Clinical Oncology, 2015, 33, 458-458.	0.8	0
86	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2017, 35, 628-628.	0.8	0
87	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. Journal of Clinical Oncology, 2017, 35, e15684-e15684.	0.8	0
88	Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S39-S39.	0.7	0
89	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. Journal of Clinical Oncology, 2019, 37, e15663-e15663.	0.8	0
90	Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.. Journal of Clinical Oncology, 2019, 37, 4075-4075.	0.8	0

#	Article	IF	Citations
91	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
92	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
93	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
94	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0